GI Dynamics appoints Mark Twyman CCO
This article was originally published in Clinica
Executive Summary
GI Dynamics, a company developing non-surgical approaches for treating type 2 diabetes and obesity, has appointed Mark Twyman to the newly created role of chief commercial officer, reporting to Stuart Randle, president and CEO. Mr Twyman has previously served at companies including MedImmune and Merck, and was most recently senior vice-president and general manager at Genzyme Biosurgery.